

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



May 15, 2026

Company name: Mochida Pharmaceutical Co., Ltd.
Name of representative: Naoyuki Mochida, Representative Director, President
(Securities code: 4534 Prime Market, TSE)
Inquiries: Public Relations, Corporate Planning Department
(Telephone: +81-3-3225-6303)

Notice Concerning Changes in Directors

Mochida Pharmaceutical Co., Ltd. (hereinafter, “the Company”) hereby announces that, at a meeting of its Board of Directors held on May 15, 2026, it resolved changes in directors and Audit & Supervisory Board Members as set forth below.

(Effective June 25, 2026)

1. Changes in Representative Directors

(1) Changes in Duties of Representative Directors

New Title	Name	Current Title
Representative Director, Senior Executive Managing Officer Supervisor for Research, Biomaterials Business, Pharmaceutical Business, Mochida Pharmaceutical Plant and Mochida Healthcare	Junichi Sakaki	Representative Director, Senior Executive Managing Officer Supervisor for Research, Pharmaceutical Development, Business Development, Business Promotion, Biomaterials Business, Pharmaceutical Business, Mochida Pharmaceutical Plant and Mochida Healthcare
Representative Director, Senior Executive Managing Officer Planning & Administration, Strategic Alliance, Legal and Audits, Supervisor for RA, QA and PV	Motoi Mitsuishi	Representative Director, Senior Executive Managing Officer Planning & Administration, Strategic Alliance and Audits, Supervisor for RA, QA and PV, Head of Planning & Administration Division

2. Candidates for Director

New Title	Name	Current Title
Member of the Board, Executive Managing Officer Business Development and Business Promotion	Takeshi Mochida	Executive Officer Deputy Head of Clinical Research and Development Division

Note: The new Director will assume office upon the approval of the resolution at the Annual General Meeting of Shareholders scheduled to be held on June 25, 2026.

3. Changes in Directors

(1) Changes in Duties of Directors

New Title	Name	Current Title
Member of the Board, Executive Managing Officer Pharmaceutical Business and Mochida Healthcare	Kenji Miyajima	Member of the Board, Executive Managing Officer Pharmaceutical Business

(2) Outgoing Directors

New Title	Name	Current Title
Advisor	Yutaka Kawakami	Member of the Board, Executive Managing Officer Mochida Pharmaceutical Plant and Mochida Healthcare

4. Candidates for Audit & Supervisory Board Members

New Title	Name	Current Title
Full-time Audit & Supervisory Board Member	Reiko Nakano	Deputy Head of Business Development Division

Note: The new Audit & Supervisory Board Member will assume office upon the approval of the resolution at the Annual General Meeting of Shareholders scheduled to be held on June 25, 2026.

5. Changes in Audit & Supervisory Board Members

(1) Outgoing Audit & Supervisory Board Members

New Title	Name	Current Title
Advisor	Masayoshi Takeda	Full-time Audit & Supervisory Board Member

###